The clinical utility of methicillin-resistant staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: A diagnostic meta-analysis with antimicrobial stewardship implications

Clinical Infectious Diseases

Volumn 67, Issue 1, 2018, Pages 1-7

  Parente, Diane M ^a   Cunha, Cheston B ^b,c   Mylonakis, Eleftherios ^b,c   Timbrook, Tristan T ^d  

^a MIRIAM HOSPITAL   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Antimicrobial stewardship; Meta analysis; MRSA nasal screening; Pneumonia

Indexed keywords

ANTIMICROBIAL STEWARDSHIP; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NOSE SMEAR; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; ISOLATION AND PURIFICATION; MASS SCREENING; MICROBIOLOGY; NOSE; NOSE CAVITY; RISK FACTOR; STAPHYLOCOCCAL PNEUMONIA;

ANTIMICROBIAL STEWARDSHIP; CROSS INFECTION; HUMANS; MASS SCREENING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NASAL CAVITY; NOSE; PNEUMONIA, STAPHYLOCOCCAL; RISK FACTORS;

EID: 85051660112     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy024     Document Type: Article

References (38)

1. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61–e111.
2. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(suppl 2):S27–72.
3. Dellit TH, Owens RC, McGowan JE Jr, et al; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159–77.
4. Giancola SE, Nguyen AT, Le B, et al. Clinical utility of a nasal swab methicillin-resistant Staphylococcus aureus polymerase chain reaction test in intensive and intermediate care unit patients with pneumonia. Diagn Microbiol Infect Dis 2016; 86:307–10.
5. Smith MN, Erdman MJ, Ferreira JA, Aldridge P, Jankowski CA. Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction assay in critically ill patients with nosocomial pneumonia. J Crit Care 2017; 38:168–71.
6. Whiting PF, Rutjes AW, Westwood ME, et al; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155:529–36.
7. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58:882–93.
8. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
9. Chan JD, Dellit TH, Choudhuri JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus aureus as a tool to predict methicillin-resistantS.aureusventilator-associatedpneumonia.CritCareMed2012;40:1437–42.
10. Corne P, Marchandin H, Jonquet O, Campos J, Bañuls AL. Molecular evidence that nasal carriage of Staphylococcus aureus plays a role in respiratory tract infections of critically ill patients. J Clin Microbiol 2005; 43:3491–3.
11. Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014; 58:859–64.
12. Gregg Z, Heffernan DA, Monaghan SF, et al. Nasal MRSA predicts ventilator-associated pneumonia and microbiology. Surg Infect (Larchmt) 2011; 12(suppl 1):S2–82.
13. Hiett J, Patel RK, Tate V, Smulian G, Kelly A. Using active methicillin-resistant Staphylococcus aureus surveillance nasal swabs to predict clinical respiratory culture results. Am J Health Syst Pharm 2015; 72:S20–4.
14. Holmes JW, Williams MD. Methicillin-resistant Staphylococcus aureus screening and eradication in the surgical intensive care unit: is it worth it? Am J Surgery 2010; 200:827–31.
15. Jang HC, Choi OJ, Kim GS, et al. Active surveillance of the trachea or throat for MRSA is more sensitive than nasal surveillance and a better predictor of MRSA infections among patients in intensive care. PLoS One 2014; 9:e99192.
16. Johnson JA, Wright ME, Sheperd LA, Musher DM, Dang BN. Nasal methicillin-resistant Staphylococcus aureus polymerase chain reaction: a potential use in guiding antibiotic therapy for pneumonia. Perm J 2015; 19:34–6.
17. Kashuk JL, Moore EE, Price CS, et al. Patterns of early and late ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus in a trauma population. J Trauma 2010; 69:519–22.
18. Korobey M, Sadaka F, Dumm A, et al. Predictive value of methicillin-resistant Staphylococcus aureus nasal swab PCR for MRSA pneumonia. Crit Care Med 2016; 44:252.
19. Langsjoen J, Brady C, Obenauf E, Kellie S. Nasal screening is useful in excluding methicillin-resistant Staphylococcus aureus in ventilator-associated pneumonia. Am J Infect Control 2014; 42:1014–5.
20. Marouni A, Pacheco S, Bolon M, Wunderink RG. Diagnosis and treatment of pneumonia in the intensive care unit in the setting of methicillin-resistant Staphylococcus aureus surveillance. Am J Respir Crit Care Med 2010; 181.
21. McMahon K, Stryjewski G. Value of MRSA nasal swab screening for predicting invasive MRSA respiratory infection. Crit Care Med 2014; 42:A1475–A6.
22. Mullins B. Methicillin-resistant Staphylococcus aureus (MRSA) surveillance culture as a predictor for MRSA ventilator associated pneumonia. In: IDWeek, 2013. 2–6 October 2013, San Francisco CA.
23. Pollock J, Bethea A, Bown A. The clinical utility of nasal swabs as a predictor of methicillin resistant Staphylococcus aureus pneumonia. Crit Care Med 2011; 39:163.
24. Rimawi RH, Ramsey KM, Shah KB, Cook PP. Correlation between methicillin-resistant Staphylococcus aureus nasal sampling and S. aureus pneumonia in the medical intensive care unit. Infect Control Hosp Epidemiol 2014; 35:590–3.
25. Robicsek A, Suseno M, Beaumont JL, Thomson RB Jr, Peterson LR. Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling. J Clin Microbiol 2008; 46:588–92.
26. Rocha LA, Marques Ribas R, da Costa Darini AL, Gontijo Filho PP. Relationship between nasal colonization and ventilator-associated pneumonia and the role of the environment in transmission of Staphylococcus aureus in intensive care units. Am J Infect Control 2013; 41:1236–40.
27. Sanuth B, Gerardo N, Khudeira Z. Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia rate in patients with MRSA in the nares. Crit Care Med 2013; 41:A201.
28. Tilahun B, Faust AC, McCorstin P, Ortegon A. Nasal colonization and lower respiratory tract infections with methicillin-resistant Staphylococcus aureus. Am J Crit Care 2015; 24:8–12.
29. Cunha CB, Varughese CA, Mylonakis E. Antimicrobial stewardship programs (ASPs): the devil is in the details. Virulence 2013; 4:147–9.
30. Boyce JM, Pop OF, Abreu-Lanfranco O, et al. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother 2013; 57:1163–8.
31. Baby N, Faust AC, Smith T, Sheperd LA, Knoll L, Goodman EL. Nasal methicillin-resistant Staphylococcus aureus (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia. Antimicrob Agents Chemother 2017; 61.
32. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56:1129–35.
33. Paule SM, Mehta M, Hacek DM, Gonzalzles TM, Robicsek A, Peterson LR. Chromogenic media vs real-time PCR for nasal surveillance of methicillin-resistant Staphylococcus aureus: impact on detection of MRSA-positive persons. Am J Clin Pathol 2009; 131:532–9.
34. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854–62.
35. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46(suppl 5):S378–85.
36. Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis 2016; 63:300–9.
37. Pardo J, Klinker KP, Borgert SJ, Trikha G, Rand KH, Ramphal R. Time to positivity of blood cultures supports antibiotic de-escalation at 48 hours. Ann Pharmacother 2014; 48:33–40.
38. Institute of Medicine. Finding what works in health care: standards for systematic reviews. Washington, DC: National Academies Press, 2011.